Demegen, Inc. and Dow Pharmaceutical Sciences have entered into a collaborative agreement to develop certain Demegen peptides into prescription pharmaceutical products. Under the terms of this agreement, Dow Pharmaceutical Sciences will be responsible for selecting suitable Demegen compounds for several topical disease indications; developing them and filing FDA applications; along with providing certain other services Read more about Demegen And Dow Form Development Collaboration[…]